AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38310163 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 636
Study 38310163 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 0.75 mg
Number of subjects: 636
Study 38310192 — intervention group
Group type: EXPERIMENTAL
Intervention: KN046 (3 mg/kg or 5 mg/kg) combined with nab-paclitaxel
Number of subjects: 27
Study 38310232 — intervention group
Group type: EXPERIMENTAL
Intervention: YRI + mobile supervision
Number of subjects: 1200
Study 38310232 — intervention group
Group type: EXPERIMENTAL
Intervention: YRI + standard supervision
Number of subjects: 1200
Study 38310232 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 1200
Study 38310236 — intervention group
Group type: COMPARATOR
Intervention: Brush/Rinse (EO alcohol-containing mouthrinse)
Number of subjects: 270
Study 38310236 — intervention group
Group type: COMPARATOR
Intervention: Brush/Rinse (EO non-alcohol containing mouthrinse)
Number of subjects: 270
Study 38310236 — intervention group
Group type: COMPARATOR
Intervention: Brush/Floss/Rinse (EO non-alcohol containing mouthrinse)
Number of subjects: 270
Study 38310236 — intervention group
Group type: COMPARATOR
Intervention: Brush/Floss
Number of subjects: 270
Study 38310249 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam accelerated partial breast irradiation (APBI)
Number of subjects: 84
Study 38310249 — intervention group
Group type: COMPARATOR
Intervention: Moderate hypofractionated whole breast irradiation (WBI)
Number of subjects: 84
Study 38310261 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every 4 weeks
Number of subjects: 739
Study 38310261 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg at week 0, week 4, then every 8 weeks
Number of subjects: 739
Study 38310261 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab (pooled N=493)
Number of subjects: 739
Study 38310261 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 739
Study 38310261 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 739
Study 38310262 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fraction stereotactic ablative radiotherapy (SF SABR)
Number of subjects: 598
Study 38310262 — intervention group
Group type: COMPARATOR
Intervention: Multiple fraction stereotactic ablative radiotherapy (MF SABR)
Number of subjects: 598
Study 38310262 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation-related symptom questionnaire-guided healthcare provider intervention
Number of subjects: 598
Study 38310262 — intervention group
Group type: COMPARATOR
Intervention: Quality of life questionnaires only
Number of subjects: 598
Study 38310268 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIC Urinary Irritative/Obstructive subscale
Number of subjects: 347
Study 38310268 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIC Urinary Summary
Number of subjects: 347
Study 38310268 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regressions
Number of subjects: 347
Study 38310268 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex model architectures
Number of subjects: 347
Study 38310274 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery (Mazor X Stealth Edition)
Number of subjects: 300
Study 38310274 — intervention group
Group type: COMPARATOR
Intervention: Freehand surgery with 2D fluoroscopy
Number of subjects: 300
Study 38310274 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 300
Study 38310286 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (50 mg/m²) and Anlotinib
Number of subjects: 8
Study 38310565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (130 mg or ~6 mg/kg induction dose followed by 90 mg subcutaneous maintenance doses q8w or q12w)
Number of subjects: 2575
Study 38310565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single intravenous dose followed by subcutaneous maintenance doses)
Number of subjects: 2575
Study 38310863 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 702
Study 38310875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day
Number of subjects: 250
Study 38310875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 38310910 — intervention group
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M vaccine
Number of subjects: 5477
Study 38310910 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (licensed rabies vaccine [Abhayrab])
Number of subjects: 5477
Study 38310920 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 15 mg
Number of subjects: 267
Study 38310920 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 40 mg
Number of subjects: 267
Study 38310920 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 100 mg
Number of subjects: 267
Study 38310920 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg
Number of subjects: 267
Study 38310920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 38310918 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone plus fludrocortisone
Number of subjects: 562
Study 38310918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study 38311016 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano Silver Fluoride (NSF) applied once at baseline
Number of subjects: 360
Study 38311016 — intervention group
Group type: COMPARATOR
Intervention: Silver Diamine Fluoride (SDF) applied at baseline and after 6 months
Number of subjects: 360
Study 38311065 — intervention group
Group type: EXPERIMENTAL
Intervention: Faba bean protein
Number of subjects: 9
Study 38311111 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin plus bendamustine and rituximab
Number of subjects: 0
Study 38311111 — intervention group
Group type: COMPARATOR
Intervention: Brentuximab vedotin (as a comparison)
Number of subjects: 0
Study 38311207 — intervention group
Group type: EXPERIMENTAL
Intervention: GA location as assessed by the ETDRS grid
Number of subjects: 82
Study 38311207 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity
Number of subjects: 82
Study 38311207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-luminance visual acuity (LLVA)
Number of subjects: 82
Study 38311207 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading acuity and speed
Number of subjects: 82
Study 38311207 — intervention group
Group type: EXPERIMENTAL
Intervention: GA area
Number of subjects: 82
Study 38311207 — intervention group
Group type: EXPERIMENTAL
Intervention: VRQoL scores associated with different GA subfields
Number of subjects: 82
Study 38311797 — intervention group
Group type: COMPARATOR
Intervention: Nomlabofusp (25, 50, 75, or 100 mg single doses)
Number of subjects: 55
Study 38311797 — intervention group
Group type: COMPARATOR
Intervention: Nomlabofusp (25 mg daily for 4 days then every third day, 50 mg daily for 7 days then every 2 days, or 100 mg daily for 13 days)
Number of subjects: 55
Study 38311797 — intervention group
Group type: COMPARATOR
Intervention: Nomlabofusp (various dosing regimens)
Number of subjects: 55
Study 38311806 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg once daily
Number of subjects: 82
Study 38312029 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized trauma intake form (TIF)
Number of subjects: 4077
Study 38312102 — intervention group
Group type: EXPERIMENTAL
Intervention: Guadecitabine and irinotecan (Arm A)
Number of subjects: 104
Study 38312102 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (regorafenib or TAS-102) (Arm B)
Number of subjects: 104
Study 38312142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (four individual counseling sessions with a registered dietitian, 10 informative video clips, and a virtual support community)
Number of subjects: 150
Study 38312142 — intervention group
Group type: COMPARATOR
Intervention: Usual prenatal care
Number of subjects: 150
Study 38312212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 40
Study 38312212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 38312234 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 210
Study 38312234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 38312234 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 210
Study 38312318 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate brachytherapy (HDRBT)
Number of subjects: 0
Study 38312318 — intervention group
Group type: COMPARATOR
Intervention: Low-dose-rate brachytherapy (LDRBT)
Number of subjects: 0
Study 38312435 — intervention group
Group type: EXPERIMENTAL
Intervention: Halova vaginal ovules
Number of subjects: 0
Study 38312459 — intervention group
Group type: EXPERIMENTAL
Intervention: F/TAF
Number of subjects: 0
Study 38312459 — intervention group
Group type: EXPERIMENTAL
Intervention: F/TDF
Number of subjects: 0
Study 38312795 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan
Number of subjects: 68
Study 38312795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 38312972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagittal Split Plate (SSOP)
Number of subjects: 38
Study 38312972 — intervention group
Group type: COMPARATOR
Intervention: Two Miniplates
Number of subjects: 38
Study 38313142 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended cognitive-behavioral intervention (CBT) combining an Internet-based program with videoconference sessions every 10-12 days, containing seven modules.
Number of subjects: 41
Study 38313142 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended cognitive-behavioral intervention (CBT)
Number of subjects: 41
Study 38313251 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher SM Group (n = 10)
Number of subjects: 20
Study 38313251 — intervention group
Group type: COMPARATOR
Intervention: Lower SM Group (n = 10)
Number of subjects: 20
Study 38313271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-field portable MRI (ULF-pMRI)
Number of subjects: 50
Study 38313407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-coupled intensive balance training (CIBT)
Number of subjects: 32
Study 38313407 — intervention group
Group type: COMPARATOR
Intervention: Single-task training
Number of subjects: 32
Study 38313767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mirikizumab 300 mg every 4 weeks for 12 weeks (LUCENT-1)
Number of subjects: 1706
Study 38313767 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous mirikizumab 200 mg every 4 weeks through Week 40 (LUCENT-2)
Number of subjects: 1706
Study 38313767 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 12 weeks (LUCENT-1)
Number of subjects: 1706
Study 38313767 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 weeks through Week 40 (LUCENT-2)
Number of subjects: 1706
Study 38314010 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraTogs + Conventional Physical Therapy (CPT)
Number of subjects: 34
Study 38314010 — intervention group
Group type: COMPARATOR
Intervention: Conventional Physical Therapy (CPT)
Number of subjects: 34
Study 38314063 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA vaccine
Number of subjects: 100
Study 38314063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 38314087 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric CD70-Peptide Vaccine
Number of subjects: 0
Study 38314118 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time sleep duration at 6 months postpartum
Number of subjects: 0
Study 38314243 — intervention group
Group type: EXPERIMENTAL
Intervention: vWF concentrates
Number of subjects: 497
Study 38314243 — intervention group
Group type: COMPARATOR
Intervention: Platelet concentrates
Number of subjects: 497
Study 38314254 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Scouts intervention (a fixed contact person who advises, accompanies, and supports the families)
Number of subjects: 0
Study 38314254 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Scouts intervention
Number of subjects: 0
Study 38314536 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with VR glasses
Number of subjects: 58
Study 38314536 — intervention group
Group type: COMPARATOR
Intervention: Surgery without VR glasses (Control)
Number of subjects: 58
Study 38314554 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 337
Study 38314554 — intervention group
Group type: COMPARATOR
Intervention: Sham-control
Number of subjects: 337
Study 38314643 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone/Zolmitriptan (10/1.25 mg three times a day)
Number of subjects: 30
Study 38314643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 38314779 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity focused ultrasound to anterior insula (AI)
Number of subjects: 23
Study 38314779 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity focused ultrasound to posterior insula (PI)
Number of subjects: 23
Study 38314779 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 23
Study 38314943 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific PANIC cutoffs
Number of subjects: 1044
Study 38314943 — intervention group
Group type: EXPERIMENTAL
Intervention: NHANES-based cutoffs
Number of subjects: 1044
Study 38315156 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine, bupivacaine, and epinephrine
Number of subjects: 117
Study 38315156 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine and epinephrine (control group)
Number of subjects: 117
Study 38315229 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible hyaluronic acid (HA) filler, Restylane
Number of subjects: 0
Study 38315229 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study 38315466 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel
Number of subjects: 5204
Study 38315466 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 5204
Study 38315470 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab Q2W
Number of subjects: 153
Study 38315470 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab Q4W
Number of subjects: 153
Study 38315470 — intervention group
Group type: COMPARATOR
Intervention: Placebo Q2W
Number of subjects: 153
Study 38315470 — intervention group
Group type: COMPARATOR
Intervention: Placebo Q4W
Number of subjects: 153
Study 38315470 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 153
Study 38315488 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention focused on resilience
Number of subjects: 0
Study 38315489 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 0
Study 38315503 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G7 Continuous Glucose Monitoring System
Number of subjects: 0
Study 38315506 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-Rapid Insulin Analogs in Hybrid Closed-Loop Therapy
Number of subjects: 0
Study 38315506 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38315700 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic TB screening in facility-based child-health entry points, decentralisation of TB diagnosis and management, improved sample collection with access to Xpert® MTB/RIF or MTB/RIF Ultra testing, implementation of contact investigation.
Number of subjects: 1991401
Study 38315721 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth use
Number of subjects: 575
Study 38315721 — intervention group
Group type: COMPARATOR
Intervention: Living in more disadvantaged areas (based on SDI)
Number of subjects: 575
Study 38315721 — intervention group
Group type: COMPARATOR
Intervention: Driving time from home to clinic (more than an hour)
Number of subjects: 575
Study 38315721 — intervention group
Group type: COMPARATOR
Intervention: Continuity of MOUD (180 days retention)
Number of subjects: 575
Study 38315777 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (specific type not mentioned)
Number of subjects: 0
Study 38315777 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 0
Study 38315777 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal fusion to the sacrum
Number of subjects: 0
Study 38315832 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L cellular immunotherapy after SOC (n=68)
Number of subjects: 359
Study 38315832 — intervention group
Group type: COMPARATOR
Intervention: 3L therapy not receiving cellular immunotherapy after SOC (n=59)
Number of subjects: 359
Study 38315832 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L chemotherapy after axi-cel (n=60)
Number of subjects: 359
Study 38315832 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L cellular immunotherapy after axi-cel (n=8)
Number of subjects: 359
Study 38315832 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L chemotherapy with SCT after salvage chemotherapy (n=10)
Number of subjects: 359
Study 38315832 — intervention group
Group type: COMPARATOR
Intervention: 3L chemotherapy without SCT after salvage chemotherapy (n=50)
Number of subjects: 359
Study 38315832 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L cellular immunotherapy after 2L axi-cel (n=8)
Number of subjects: 359
Study 38315872 — intervention group
Group type: EXPERIMENTAL
Intervention: Single IV dose of 1080 mg
Number of subjects: 13
Study 38315872 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) dosing of 1080 mg on 3 consecutive days
Number of subjects: 13
Study 38315872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with pegcetacoplan (IV or SC)
Number of subjects: 13
Study 38315878 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 210
Study 38315878 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 210
Study 38315944 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 1.3 mg/m²
Number of subjects: 244
Study 38315944 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice chemotherapy
Number of subjects: 244
Study 38315944 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin
Number of subjects: 244
Study 38315945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinpanemab (human-derived monoclonal antibody) administered intravenously every 4 weeks for 52 weeks
Number of subjects: 357
Study 38315945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study 38315963 — intervention group
Group type: EXPERIMENTAL
Intervention: FULV + oxaliplatin (FOLFOX)
Number of subjects: 1065
Study 38315963 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil plus leucovorin (FULV)
Number of subjects: 1065
Study 38315997 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral science-informed, point-of-care, clinical decision support tools plus brief case-based education
Number of subjects: 371
Study 38315997 — intervention group
Group type: COMPARATOR
Intervention: Brief case-based education alone
Number of subjects: 371
Study 38316055 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically delivered laser power with assumed, homogeneous optical properties
Number of subjects: 13
Study 38316055 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically delivered laser power with measured, homogeneous optical properties
Number of subjects: 13
Study 38316055 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific treatment planning using measured, homogeneous optical properties
Number of subjects: 13
Study 38316133 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral decitabine 35 mg plus cedazuridine 100 mg on days 1-5 and venetoclax (400 mg) for 14 days
Number of subjects: 39
Study 38316224 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisegmented esophageal fully covered self-expandable metal stent (FCSEMS)
Number of subjects: 23
Study 38316236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative dexamethasone followed by a 6-day oral methylprednisolone taper course
Number of subjects: 67
Study 38316236 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative dexamethasone only (control group)
Number of subjects: 67
Study 38316489 — intervention group
Group type: EXPERIMENTAL
Intervention: MSB11456
Number of subjects: 604
Study 38316489 — intervention group
Group type: COMPARATOR
Intervention: EU-approved tocilizumab
Number of subjects: 604
Study 38316493 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVIGO 4LV 2D lead
Number of subjects: 217
Study 38316493 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVIGO 4LV ARC lead
Number of subjects: 217
Study 38316493 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NAVIGO 4LV leads
Number of subjects: 217
Study 38316587 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-ankle exercise programme alongside educational strategies
Number of subjects: 356
Study 38316587 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 356
Study 38316588 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral dose of three strains of probiotics
Number of subjects: 450
Study 38316588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 38316588 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 450
Study 38316595 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement with patient representatives and healthcare professionals to achieve consensus on core outcome set.
Number of subjects: 0
Study 38316595 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-Delphi approach for consensus building.
Number of subjects: 0
Study 38316600 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical weight loss
Number of subjects: 200
Study 38316600 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 200
Study 38316601 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre legume-rich entrées for two meals/day in months 1-3 and one meal/day in months 4-6.
Number of subjects: 60
Study 38316601 — intervention group
Group type: COMPARATOR
Intervention: Lean protein sources (e.g., chicken) replacing legumes in entrées.
Number of subjects: 60